Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

ANGLE plc Announces Appointments: Interim CEO and Senior Board Advisor

GUILFORD, SURREY, AL / ACCESS Newswire / October 16, 2025 / ANGLE plc (to be renamed CelLBxHealth plc) (AIM:AGL)(OTCQX:ANPCY), a world-leading circulating tumour cell (CTC) intelligence company with tests for use in research, drug development and clinical oncology, announces that it has strengthened its management team through two senior hires.

Peter Collins has been appointed as interim Chief Executive Officer of the Company and Klaas de Boer joins as a senior advisor to the Board.

Peter Collins brings over 25 years of experience in oncology drug and diagnostics development, having held senior executive positions across both private and publicly listed companies. He joins the Company following a series of successful leadership roles at leading oncology diagnostics organisations, including Chief Executive Officer at SAGA Diagnostics, Chief Business Officer at Inivata, Vice President, Biopharma Business Development at Guardant Health, and Head of Diagnostics at GSK.

Throughout his career, Peter has demonstrated a consistent record of building high-performing teams and driving commercial growth across international healthcare markets. As interim CEO, he joins the Company in a non-board capacity.

Klaas de Boer holds numerous board positions with both public and private international companies including Xeros plc, SmartKem, Inc. and General Fusion, Inc. He began his career with McKinsey & Company before transitioning to venture capital more than 25 years ago; initially with Baan Investment, and later as Managing Partner with Entrepreneurs Fund. His experience in the finance and technology sectors will be invaluable as the Company goes through a restructure and funding in Q4.

Dr Jan Groen, Executive Chairman commented:

"Peter is an exceptional leader with a proven track record of commercial excellence, disciplined execution, and innovation. The Board is delighted that he has agreed to serve as interim CEO while we continue the process to make a permanent appointment. We are also delighted to have Klaas assisting the Board and management team during the coming period."

For further information:

ANGLE plc

Dr Jan Groen, Executive Chairman

+44 (0) 1483 343434

investors@angleplc.com

Cavendish (NOMAD and Broker)

Geoff Nash / Isaac Hooper (Corporate Finance)

Sunila de Silva (Corporate Broking)

Nigel Birks (Life Science Specialist Sales)

+44 (0) 20 7220 0500

FTI Consulting

Simon Conway, Ciara Martin, Sam Purewal

Matthew Ventimiglia (US)

+44 (0) 203 727 1000

+1 (212) 850 5624

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the EU Market Abuse Regulation (596/2014).Upon the publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/

Notes for editors

About ANGLE plc (to be re-named CelLBxHealth plc)

ANGLE plc is a global precision CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology. Its patent-protected Parsortix® platform harvests CTCs from blood and enables comprehensive downstream analysis - including whole-cell imaging, proteomic profiling and full genomic workflows - supporting research, drug development and clinical oncology.

Commercial activities centre on (i) biopharma clinical services, (ii) partnerships, (iii) development of laboratory-developed tests (LDTs), and (iv) Research Use Only validation of existing commercial proteomic and genomic assays. The product portfolio comprises the Parsortix® platform with associated consumables and assays. Biopharma services are delivered from ANGLE's GCLP-compliant UK laboratory, providing bespoke LDT development, clinical-trial testing and custom services.

For more information, visit www.angleplc.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: ANGLE plc



View the original press release on ACCESS Newswire

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  213.04
-1.43 (-0.67%)
AAPL  252.29
+4.84 (1.96%)
AMD  233.08
-1.48 (-0.63%)
BAC  51.28
+0.84 (1.67%)
GOOG  253.79
+1.91 (0.76%)
META  716.91
+4.84 (0.68%)
MSFT  513.58
+1.97 (0.39%)
NVDA  183.16
+1.35 (0.74%)
ORCL  291.31
-21.69 (-6.93%)
TSLA  439.31
+10.56 (2.46%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.